文献速递糖尿病

C肽指标对1型糖尿病β细胞替代治疗临床结局的预测价值:来自协作胰岛移植注册中心(CITR)的报告

Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR).
PubMed 文献 · Diabetes Care · 2023-01-01

基于CITR中677例胰岛单独移植受者(移植前C肽<0.1 nmol/L,平均随访4.6±1.1年),用ROC-AUC评估空腹及刺激后血糖和C肽指标对7项主要结局的预测价值。空腹C肽对无严重低血糖事件(ASHE)预测性高(ROC-AUC 0.906,最佳切点0.070 nmol/L),对最优结局的ROC-AUC为0.845、最佳切点0.33 nmol/L;混合餐耐量试验(MMTT)刺激的C肽-血糖比(CPGR)除ASHE外所有结局预测均优于空腹及刺激后C肽。

要点

  • 空腹C肽可可靠预测胰岛移植主要结局,ASHE的ROC-AUC为0.906、切点0.070 nmol/L。
  • 无MMTT时,空腹C肽≥0.33 nmol/L提示最佳胰岛移植物功能。
  • MMTT刺激的CPGR对复合结局(含胰岛素非依赖)预测略优于C肽。

核心结论

  • 空腹C肽可可靠预测胰岛移植主要结局,MMTT刺激的CPGR对复合结局(包括胰岛素非依赖)预测略优。
  • 无MMTT时,空腹C肽≥0.33 nmol/L是提示最佳胰岛移植物功能的可靠指标。
  • C肽目标可作为预测胰岛移植后血糖控制结局的简便手段,并应被视为β细胞替代治疗的潜在目标。

研究设计与样本

  • 评估协作胰岛移植注册中心(CITR)中移植前C肽<0.1 nmol/L的胰岛单独移植受者,平均随访4.6±1.1年,n=677。
  • 采用受试者工作特征曲线下面积(ROC-AUC)评估空腹及刺激后血糖和C肽指标对7项主要结局的预测价值,并选择ROC-AUC最高的指标确定最佳切点。

主要发现

  • 空腹C肽对ASHE高度预测(ROC-AUC 0.906;最佳切点0.070 nmol/L),对最优结局的ROC-AUC为0.845、最佳切点0.33 nmol/L。
  • MMTT刺激的CPGR除ASHE外所有结局的预测均优于空腹及刺激后C肽。
  • 最优结局的MMTT刺激CPGR最佳切点为0.12 nmol/mmol,MMTT刺激C肽最佳切点为0.97 nmol/L。

关键数值与推荐

  • 空腹C肽预测ASHE的ROC-AUC 0.906,最佳切点0.070 nmol/L。
  • 空腹C肽预测最优结局的ROC-AUC 0.845,最佳切点0.33 nmol/L。
  • 最优结局的MMTT刺激CPGR最佳切点为0.12 nmol/mmol,MMTT刺激C肽最佳切点为0.97 nmol/L。

临床怎么用

  • 空腹C肽可可靠预测胰岛移植主要结局,无MMTT时空腹C肽≥0.33 nmol/L是提示最佳胰岛移植物功能的可靠指标。
  • 作者认为C肽目标可作为预测胰岛移植后血糖控制结局的简便手段,并应被视为β细胞替代治疗的潜在目标。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine C-peptide measures and levels associated with positive glycemic control outcomes following islet transplant (ITx) in type 1 diabetes. RESEARCH DESIGN AND METHODS: We evaluated Collaborative Islet Transplant Registry (CITR) islet-alone recipients with pretransplant C-peptide <0.1 nmol/L and mean follow-up of 4.6 ± 1.1 years (n = 677). Receiver operating characteristic area under the curve (ROC-AUC) was used to evaluate the predictive value of fasting and stimulated glucose and C-peptide measures for seven primary outcomes: 1) absence of severe hypoglycemic events (ASHEs); 2) HbA1c <7.0%; 3) HbA1c <7.0% and ASHEs; 4) HbA1c ≤6.5%; 5) HbA1c ≤6.5% and ASHEs; 6) insulin independence; and 7) ASHEs, HbA1c ≤6.5%, and insulin independence (the optimal outcome). Measures with the highest ROC-AUC were selected for determination of optimal cut points. RESULTS: Fasting C-peptide was highly predictive for ASHE (ROC-AUC 0.906; optimal cut point 0.070 nmol/L) and the optimal outcome (ROC-AUC 0.845; optimal cut point 0.33 nmol/L). Mixed-meal tolerance test (MMTT)-stimulated C-peptide-to-glucose ratio (CPGR) outperformed both fasting and stimulated C-peptide for all outcomes except ASHE. The optimal cut point for the optimal outcome was 0.12 nmol/mmol for MMTT-stimulated CPGR and 0.97 nmol/L for MMTT-stimulated C-peptide. CONCLUSIONS: Fasting C-peptide reliably predicts ITx primary outcomes. MMTT-stimulated CPGR provides marginally better prediction for composite ITx outcomes, including insulin independence. In the absence of an MMTT, a fasting C-peptide ≥0.33 nmol/L is a reassuring measure of optimal islet graft function. C-peptide targets represent excellent and easily determinable means to predict glycemic control outcomes after ITx and should be considered as potential goals of β-cell replacement.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Baidal DA, Ballou CM, Rickels MR, et al. Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR). Diabetes Care. 2023. PMID: 36657975. doi:10.2337/dc22-1155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。